Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 23, 2020

Primary Completion Date

November 2, 2020

Study Completion Date

April 5, 2021

Conditions
COVID 19
Interventions
DRUG

1: ILT101

Subcutaneous injections, once-daily administration for 10 consecutive days.

DRUG

2: Placebo Comparator

placebo in Subcutaneous route

Trial Locations (1)

75013

Service Anesthésie Réanimation - Groupe Hospitalier Pitié-Salpêtrière, Paris

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Iltoo Pharma

INDUSTRY

lead

Assistance Publique - Hôpitaux de Paris

OTHER